JBF Capital’s Regeneron Pharmaceuticals REGN Stock Holding History

JBF Capital’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.86M	Hold	5,000	–	–	0.57%	21
2025 Q4	$3.86M	Buy	+5,000	New	+$3.4M	0.56%	19

Other funds holding REGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

JBF Capital's REGN Position: Q1 2026 in Review

JBF Capital held its Regeneron Pharmaceuticals (REGN) position steady in Q1 2026 at 5,000 shares worth $3.86M. The position accounts for 0.57% of the portfolio, ranked #21.

JBF Capital first reported a position in REGN in Q4 2025 and has held it in 2 quarters since. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

JBF Capital held 5,000 shares of Regeneron Pharmaceuticals worth $3.86M as of Q1 2026.
JBF Capital left its Regeneron Pharmaceuticals share count unchanged in Q1 2026.
Regeneron Pharmaceuticals made up 0.57% of JBF Capital's portfolio in Q1 2026, its #21 holding.
JBF Capital first reported a position in Regeneron Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on JBF Capital's 13F filing for Q1 2026, filed 8 May 2026.